• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Executive Officer Hsieh Ming covered exercise/tax liability with 2,949 shares, decreasing direct ownership by 0.33% to 897,685 units (SEC Form 4) (withholding tax)

    5/27/26 7:42:21 PM ET
    $FLGT
    Medical Specialities
    Health Care
    Get the next $FLGT alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hsieh Ming

    (Last)(First)(Middle)
    C/O FULGENT GENETICS, INC.
    4399 SANTA ANITA AVENUE

    (Street)
    EL MONTE CALIFORNIA 91731

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Fulgent Genetics, Inc. [ FLGT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirectorX10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Executive Officer
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    05/26/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock05/26/2026F2,949(1)D$17.67897,685D
    Common Stock7,895,115IBy Trust(2)
    Common Stock220,816IBy Trust(3)
    Common Stock1,000IUniform Transfer to Minor Account(4)
    Common Stock1,000IBy Immediate Family(5)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024.
    2. Securities held by The Ming Hsieh Trust (the "Hsieh Trust"). Mr. Hsieh is the trustee of the Hsieh Trust and possesses the sole voting and dispositive power with respect to securities held by the Hsieh Trust.
    3. Securities held by the Dynasty Trust. Mr. Hsieh is the grantor of the Dynasty Trust and he and his spouse, Eva Hsieh, and Jian Xie serve on the investment committee of the Dynasty Trust. Mr. Hsieh disclaims any beneficial interest except with respect to any pecuniary interest therein.
    4. Shares held in a Uniform Transfers to Minor Act account for which Ming Hsieh acts as custodian and possesses the sole voting and dispositive power.
    5. Shares, which were previously held in a Uniform Transfers to Minor Act account, now held by an immediate family member residing in the same household as Ming Hsieh.
    /s/ Paul Kim as Attorney-in-Fact05/27/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $FLGT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FLGT

    DatePrice TargetRatingAnalyst
    8/5/2025$30.00Neutral → Buy
    UBS
    12/7/2023$35.00Neutral
    UBS
    12/8/2022$65.00 → $40.00Overweight → Neutral
    Piper Sandler
    11/18/2022$45.00Outperform
    Raymond James
    8/25/2022$65.00Outperform
    Credit Suisse
    2/4/2022$80.00Overweight
    Piper Sandler
    1/25/2022$141.00 → $125.00Outperform
    Oppenheimer
    8/10/2021$55.00 → $65.00Underperform
    Credit Suisse
    More analyst ratings

    $FLGT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Xie Jian sold $38,382 worth of shares (2,146 units at $17.89), decreasing direct ownership by 0.58% to 367,605 units (SEC Form 4) (tax withholding)

    4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

    6/3/26 5:29:54 PM ET
    $FLGT
    Medical Specialities
    Health Care

    CFO and Treasurer Kim Paul covered exercise/tax liability with 2,087 shares, decreasing direct ownership by 0.57% to 362,545 units (SEC Form 4) to cover taxes

    4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

    6/3/26 5:29:45 PM ET
    $FLGT
    Medical Specialities
    Health Care

    Chief Scientific Officer Gao Hanlin sold $30,191 worth of shares (1,688 units at $17.89), decreasing direct ownership by 0.17% to 990,374 units (SEC Form 4) (withholding obligation)

    4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

    6/3/26 5:29:37 PM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fulgent Presents Updated FID-007 Data at ASCO 2026

    Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago. The abstract, entitled "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020," will present updated preliminary data from the Company's open-label, randomized Phase 2 study (NCT0633

    6/1/26 7:00:00 PM ET
    $FLGT
    Medical Specialities
    Health Care

    Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

    Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on the ASCO 2026 website. The abstract will be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) Rapid Oral Abstract Session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in Hall D1 of McCormick Place, Chicago. The abstract is entitled "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020". It presents interim data from th

    5/21/26 5:03:00 PM ET
    $FLGT
    Medical Specialities
    Health Care

    Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics

    New solution helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care FoundationOne PGx includes genes associated with the metabolism of medicines that have strong clinical evidence and actionable guidelines, including DPYD Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced plans to launch FoundationOne®PGx, a pharmacogenetic (PGx) offering to identify genetic differences that influence how medicines are metabolized and processed by the body. FoundationOne PGx will be offered in the United States through a partnership with Fulgent Genetics, Inc. (NASDAQ:FLGT) and will be available to order thro

    5/4/26 7:00:00 AM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Fulgent Genetics Inc.

    SCHEDULE 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)

    5/27/26 7:42:47 PM ET
    $FLGT
    Medical Specialities
    Health Care

    Fulgent Genetics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Fulgent Genetics, Inc. (0001674930) (Filer)

    5/21/26 5:04:12 PM ET
    $FLGT
    Medical Specialities
    Health Care

    SEC Form S-8 filed by Fulgent Genetics Inc.

    S-8 - Fulgent Genetics, Inc. (0001674930) (Filer)

    5/14/26 4:59:48 PM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and Treasurer Kim Paul bought $1,596,470 worth of shares (100,000 units at $15.96), increasing direct ownership by 40% to 348,282 units (SEC Form 4)

    4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

    3/5/25 6:47:40 PM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fulgent Genetics upgraded by UBS with a new price target

    UBS upgraded Fulgent Genetics from Neutral to Buy and set a new price target of $30.00

    8/5/25 7:03:39 AM ET
    $FLGT
    Medical Specialities
    Health Care

    UBS initiated coverage on Fulgent Genetics with a new price target

    UBS initiated coverage of Fulgent Genetics with a rating of Neutral and set a new price target of $35.00

    12/7/23 6:19:41 AM ET
    $FLGT
    Medical Specialities
    Health Care

    Fulgent Genetics downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Fulgent Genetics from Overweight to Neutral and set a new price target of $40.00 from $65.00 previously

    12/8/22 7:45:09 AM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Leadership Updates

    Live Leadership Updates

    View All

    Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

    Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics ("Bako"), a premier pathology laboratory headquartered in Alpharetta, GA and to acquire StrataDx, a premier dermatopathology laboratory located in Lexington, MA. Fulgent will acquire certain assets of Bako Diagnostics and will acquire StrataDx for a total combined purchase price of approximately $55.5 m

    12/22/25 4:10:00 PM ET
    $FLGT
    Medical Specialities
    Health Care

    DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

    3/7/25 6:19:00 PM ET
    $ALK
    $AMBC
    $ATI
    Air Freight/Delivery Services
    Consumer Discretionary
    Property-Casualty Insurers
    Finance

    Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing

    PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 year

    6/10/24 1:00:00 AM ET
    $FLGT
    $NEO
    Medical Specialities
    Health Care
    Precision Instruments

    $FLGT
    Financials

    Live finance-specific insights

    View All

    Fulgent Reports First Quarter 2026 Financial Results

    Reiterates revenue guidance for fiscal year 2026 Executed on stock repurchase program; purchased approximately 2.6 million shares in the first quarter of 2026 using $40.1 million in cash Revenue of $71.1 million GAAP gross profit of $21.5 million, or GAAP gross margin of 30.2%; Non-GAAP gross profit of $23.0 million, or Non-GAAP gross margin of 32.3% GAAP loss of $24.8 million, or $(0.80) per share; Non-GAAP loss of $11.0 million, or $(0.36) per share Ended the first quarter of 2026 with $604.7 million of cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of approximately $106 million Fulgent Genetics, In

    5/1/26 7:00:00 AM ET
    $FLGT
    Medical Specialities
    Health Care

    Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

    Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2026 financial results before the market opens on Friday, May 1, 2026. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is a

    4/16/26 7:30:00 AM ET
    $FLGT
    Medical Specialities
    Health Care

    Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of $83.3 million, growing 9% year-over-year GAAP gross profit of $32.6 million, or GAAP gross margin of 39.1%; Non-GAAP gross profit of $34.2 million, or Non-GAAP gross margin of 41.0% GAAP loss of $23.4 million, or ($0.76) per share; Non-GAAP income of $5.2 million, or $0.16 per share Ended the year with $705.5 million of cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of approximately $106.3 million Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announce

    2/27/26 7:00:00 AM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Fulgent Genetics Inc.

    SC 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)

    11/5/24 4:46:55 PM ET
    $FLGT
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Fulgent Genetics Inc. (Amendment)

    SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

    1/23/24 4:13:58 PM ET
    $FLGT
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Fulgent Genetics Inc. (Amendment)

    SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

    1/26/23 8:52:11 AM ET
    $FLGT
    Medical Specialities
    Health Care